

RESEARCH ARTICLE

Open Access



RNA-seq and Tn-seq reveal fitness determinants of vancomycin-resistant *Enterococcus faecium* during growth in human serum

Xinglin Zhang^{1,2}, Vincent de Maat², Ana M. Guzmán Prieto², Tomasz K. Prajsnar³, Jumamurat R. Bayjanov², Mark de Been², Malbert R. C. Rogers², Marc J. M. Bonten², Stéphane Mesnage³, Rob J. L. Willems² and Willem van Schaik^{2,4*} 

Abstract

Background: The Gram-positive bacterium *Enterococcus faecium* is a commensal of the human gastrointestinal tract and a frequent cause of bloodstream infections in hospitalized patients. The mechanisms by which *E. faecium* can survive and grow in blood during an infection have not yet been characterized. Here, we identify genes that contribute to growth of *E. faecium* in human serum through transcriptome profiling (RNA-seq) and a high-throughput transposon mutant library sequencing approach (Tn-seq).

Results: We first sequenced the genome of *E. faecium* E745, a vancomycin-resistant clinical isolate, using a combination of short- and long read sequencing, revealing a 2,765,010 nt chromosome and 6 plasmids, with sizes ranging between 9.3 kbp and 223.7 kbp. We then compared the transcriptome of *E. faecium* E745 during exponential growth in rich medium and in human serum by RNA-seq. This analysis revealed that 27.8% of genes on the *E. faecium* E745 genome were differentially expressed in these two conditions. A gene cluster with a role in purine biosynthesis was among the most upregulated genes in *E. faecium* E745 upon growth in serum. The *E. faecium* E745 transposon mutant library was then used to identify genes that were specifically required for growth of *E. faecium* in serum. Genes involved in de novo nucleotide biosynthesis (including *pyrK_2*, *pyrF*, *purD*, *purH*) and a gene encoding a phosphotransferase system subunit (*manY_2*) were thus identified to be contributing to *E. faecium* growth in human serum. Transposon mutants in *pyrK_2*, *pyrF*, *purD*, *purH* and *manY_2* were isolated from the library and their impaired growth in human serum was confirmed. In addition, the *pyrK_2* and *manY_2* mutants were tested for their virulence in an intravenous zebrafish infection model and exhibited significantly attenuated virulence compared to *E. faecium* E745.

Conclusions: Genes involved in carbohydrate metabolism and nucleotide biosynthesis of *E. faecium* are essential for growth in human serum and contribute to the pathogenesis of this organism. These genes may serve as targets for the development of novel anti-infectives for the treatment of *E. faecium* bloodstream infections.

Keywords: *Enterococcus faecium*, Transcriptome, Transposon mutant library screening, Nucleotide biosynthesis, Carbohydrate metabolism, Virulence, Zebrafish

* Correspondence: w.vanschaik@bham.ac.uk

²Department of Medical Microbiology, University Medical Center Utrecht, 3584CX Utrecht, the Netherlands

⁴Institute of Microbiology and Infection, College of Medical and Dental Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom

Full list of author information is available at the end of the article



Background

Enterococci are commensals of the gastrointestinal tract of humans and animals, but some enterococcal species, particularly *E. faecium* and *E. faecalis*, are also common causes of hospital-acquired infections in immunocompromised patients [1]. While *E. faecalis* has been recognized as an important nosocomial pathogen for over a century, *E. faecium* has emerged as a prominent cause of hospital-acquired infections over the last two decades [2]. Since the 1980s, *E. faecium* acquired resistance to multiple antibiotics, including β -lactams, aminoglycosides and finally, to the glycopeptide vancomycin [3]. Nosocomial infections are almost exclusively caused by a specific sub-population of *E. faecium*, termed clade A-1, which has emerged from a background of human commensal and animal *E. faecium* strains [4]. Strains in clade A-1 carry genetic elements that are absent from animal or human commensal isolates and which contribute to gut colonization or pathogenicity [5–9]. Clade A-1 *E. faecium* strains are rarely found in healthy individuals but can colonize the gut of immunosuppressed, hospitalized patients to high-levels. These strains can then cause infections by direct translocation from the gut into the bloodstream [10–12]. In addition, due to faecal contamination of the skin in hospitalized patients, the use of intravenous catheters is another risk factor for the introduction of *E. faecium* into the bloodstream [3, 13, 14]. Currently, *E. faecium* causes approximately 40% of enterococcal bacteremias. Due to the accumulation of antibiotic resistance determinants in clade A-1 strains, *E. faecium* infections are more difficult to treat than infections caused by *E. faecalis* or other enterococci [15–17]. To cause bloodstream infections, *E. faecium* needs to be able to survive and multiply in blood, but the mechanisms by which it can do so, have not yet been studied. To thrive in the bloodstream, an opportunistic pathogen has to evade host immune mechanisms and to adjust its metabolism to an environment that is relatively poor in nutrients [18].

To identify genes that are conditionally essential in bacteria, high-throughput screening methods for transposon mutant libraries have been developed and optimized for many different bacterial species [19, 20]. To perform high-throughput functional genomics in ampicillin-resistant, vancomycin-susceptible clinical *E. faecium* strains, we previously developed a microarray-based transposon mutagenesis screening method which was used to identify genes involved in the development of endocarditis [7], resistance to ampicillin [21], bile [22] and disinfectants [23]. However, microarray-based methods for transposon mutant library screening are limited in their accuracy and can only be used in strains for which the microarray was designed. To address these limitations, several methods, including Tn-seq [24] and TraDIS [25], which are based

on high-throughput sequencing of the junctions of the transposon insertion sites and genomic DNA, have been developed [26].

In this study, we set-up Tn-seq in the clinical *E. faecium* isolate E745 to identify genes that contribute to survival and growth in human serum. In addition, we determined the transcriptional response of *E. faecium* E745 in that same environment. Finally, we substantiated the role of two *E. faecium* genes that contribute to growth in serum and in virulence, in a zebrafish model of infection. Collectively, our findings show that metabolic adaptations are key to *E. faecium* growth in serum and contribute to virulence.


Results

The complete genome sequence of *E. faecium* E745

In this study, we implemented RNA-seq and Tn-seq analyses in *E. faecium* strain E745, an ampicillin- and vancomycin-resistant clinical isolate. *E. faecium* E745 was isolated from a rectal swab of a hospitalized patient as part of routine surveillance during an outbreak of VRE in the nephrology ward of a Dutch hospital in 2000 [27, 28]. To allow the application of RNA-seq and Tn-seq in *E. faecium* E745, we first determined the complete genome sequence of this strain through a combination of short-read Illumina sequencing and long-read sequencing on the RSII Pacific Biosciences and Oxford NanoPore's MinION systems. This resulted in a closed chromosomal sequence of 2,765,010 nt and 6 complete plasmids sequences, with sizes ranging between 9.3 kbp and 223.7 kbp (Additional file 1). Taken together, the chromosome and plasmids have 3095 predicted coding sequences. Phylogenetic analysis of the core genome of E745 and a set of 72 genomes representing global *E. faecium* diversity [4], showed that *E. faecium* E745 is a clade A-1 strain (Fig. 1). The E745 chromosome contains a pathogenicity island with the *esp* gene, which encodes a 207-kDa surface protein that is involved in biofilm formation and infection [6, 29, 30]. The vancomycin resistance genes of *E. faecium* E745 are of the *vanA* type [31] and are carried on the 32.4-kbp plasmid pE745-2. Additional antibiotic resistance genes in the *E. faecium* E745 genome are the trimethoprim resistance gene *dfrG* [32], which is located on plasmid pE745-6, and the chromosomally encoded macrolide resistance gene *msrC* [33].

Transcriptome of *E. faecium* E745 during growth in rich medium and in human serum

After confirming that serum can support the growth of *E. faecium* E745, though at a lower growth rate than the rich medium BHI (Additional file 2), the transcriptional profile of E745 was determined by RNA-seq during exponential growth in BHI and in heat-inactivated human



or was heat-treated to inactivate the complement system [34]. Minor differences were observed among conditionally essential genes between the experiments performed in native human serum or heat-inactivated human serum (Additional file 7) and the following results correspond to the experiments obtained with heat-inactivated serum. This condition was chosen because it may be a more reproducible in vitro environment, particularly since the interaction between the complement system and Gram-positive bacteria remains to be fully elucidated [35, 36].

We identified 37 genes that significantly contributed to growth of E745 in human serum (Fig. 3 and Additional file 8): twenty-nine genes were located on the chromosome and eight genes were present on plasmids (six genes on pE745-5, two genes on plasmid pE745-6). The relatively large number of genes identified indicates

that growth of *E. faecium* in human serum is a multifactorial process. The genes that conferred the most pronounced effect on growth of *E. faecium* in serum included genes that are involved in carbohydrate uptake (*manZ_3*, *manY_2*, *ptsL*), a putative transcriptional regulator (*algB*) and genes involved in the biosynthesis of purine and pyrimidine nucleotides (*guaB*, *purA*, *pyrF*, *pyrK_2*, *purD*, *purH*, *purL*, *purQ*, *purC*) (Fig. 3). Notably, the *purD*, *purH*, and *purL* genes were found to exhibit higher expression upon growth in human serum in the RNA-seq analysis (Fig. 2). Nine genes were identified as negatively contributing to growth in serum, i.e. the transposon mutants in these genes were significantly enriched upon growth in serum. The effects of these mutations were relatively limited (Additional file 8), compared to the major effects observed in the transposon mutants discussed above,




Fig. 3 Tn-seq analysis to identify *E. faecium* genes required for growth in human serum. Bubbles represent genes, and bubble size corresponds to the fold-changes (for visual reasons, a 100-fold change in transposon mutant abundance is set as a maximum) derived from the read-count ratio of libraries grown in BHI to libraries grown in human serum. On the x-axis genes are shown in order of their genomic location and the chromosome and plasmids are indicated. The outcome of statistical analysis of the Tn-seq data is indicated on the y-axis. Genes with a significant change ($q < 0.05$) in fitness in serum versus BHI are grouped by function and are labelled with different colors, and the name or locus tag and the change in abundance between the control condition and growth in serum is indicated next to the bubbles in parentheses. Negative values indicate that mutants in these genes outgrow other mutants in serum, suggesting that these mutants, compared to the wild-type strain *E. faecium* E745, have a higher fitness in serum

but it is notable that five (*clsA_1*, *ddcP*, *ldt_{fmm}*, *mgs*, and *lytA_2*) of these genes have predicted roles in cell wall and cytoplasmic membrane biosynthesis.

We developed a PCR-based method (Additional file 9) to selectively isolate five transposon mutants (in the purine metabolism genes *purD* and *purH*, the pyrimidine metabolism genes *pyrF* and *pyrK_2* and the phosphotransferase system (PTS) gene *manY_2* from the transposon library. Growth in rich medium of these transposon insertion mutants was equal to the parental strain. However, all mutants were significantly impaired in their growth in human serum (Fig. 4a), confirming the results of the Tn-seq experiments.


E. faecium pyrK_2 and *manY_2* contribute to intravenous infection of zebrafish

Finally, we investigated whether the transposon insertion mutants in the *manY_2* and *pyrK_2* genes were attenuated in vivo (Fig. 4b). The mutants in these genes were selected because they represent the mutants in nucleotide and carbohydrate metabolism genes that were previously shown to contribute to the growth of *E. faecium* in human serum. As a model for intravenous infection, we used a recently described model in which *E. faecium* was injected into the circulation of zebrafish embryos to mimic systemic infections [37]. We showed that both the *manY_2* and the *pyrK_2* mutant were significantly less virulent than the parental strain. At 92 h post infection, survival of zebrafish embryos infected with the WT strain was 53%, as compared to 88% and 83% for zebrafish embryos that were infected with the transposon insertion mutants in *manY_2* and *pyrK_2*, respectively.

Discussion

E. faecium can contaminate the skin and from there colonize indwelling devices such as intravenous catheters, or it can translocate from the gastrointestinal tract in immunosuppressed patients, leading to the development of bacteremia and endocarditis. *E. faecium* infections are often difficult to treat, due to the multi-drug resistant character of the strains causing nosocomial infections [3, 4]. However, the bloodstream poses challenges for the proliferation and survival of *E. faecium*, including a scarcity of nutrients.

In the present study, we sequenced the complete genome of a vancomycin-resistant *E. faecium* strain, and identified *E. faecium* genes that were essential for growth in human serum. A total of 37 genes, including genes with roles in carbohydrate uptake and nucleotide biosynthesis, were found to be required for fitness of *E. faecium* E745 in serum. Previously, fitness determinants for growth in human serum have been identified through large-scale screening of mutant libraries in both a Gram-negative (*Escherichia coli*) and a Gram-positive (*Streptococcus pyogenes*) pathogen [38, 39]. Notably, these studies have also identified the ability for de novo synthesis of purines and pyrimidines as a crucial factor for growth in serum. In addition, in diverse pathogenic bacteria (including *Burkholderia cepacia*, *Pasteurella multocida*, *Acinetobacter baumannii*, *Salmonella enterica* serovar Typhimurium, *Bacillus anthracis*, and *Streptococcus pneumoniae*), nucleotide biosynthesis contributes importantly to virulence [40–45]. The ability to synthesize nucleotides de novo thus appears to be an essential trait for the success of a pathogen that spreads through the bloodstream [38]. The



data presented here indicate that de novo biosynthesis of nucleotides is also required for *E. faecium* growth in serum and virulence. The nucleotide biosynthesis pathway of *E. faecium* may be a promising target for the development of novel antimicrobials for the treatment of *E. faecium* bloodstream infections. Indeed, compounds that target guanine riboswitches, thereby inhibiting nucleotide biosynthesis, have already shown their efficacy in a *Staphylococcus aureus* infection model [46].

Three genes, *ptsL*, *manY_2* and *manZ_3*, encoding subunits of *E. faecium* PTSs were found to contribute to

growth in serum in our Tn-seq experiments. The *ptsL* gene is predicted to encode an enzyme that confers a phosphate group from phosphoenolpyruvate to Enzyme I of PTS, while *manY_2* and *manZ_3* are predicted to form the IIA and IIBC components of a permease system that is homologous (64% and 69% amino acid identity, respectively) to the PtnAB PTS permease of *Lactococcus lactis* MG1363. PtnAB is one of the glucose uptake systems of *L. lactis* [47] and the *E. faecium* homolog may have a similar function, which could explain its essential role during growth in serum, as glucose is the only carbohydrate that occurs in the free state in appreciable amounts in serum [18].

It is notable that among the nine genes that exhibited increased fitness upon inactivation by transposon insertion, five genes are predicted to have a role in cell wall or cytoplasmic membrane biosynthesis. The protein encoded by *ddcP* was previously characterized as a low-molecular-weight penicillin-binding protein with D-alanyl-D-alanine carboxypeptidase activity [21], while *ldt_{fm}* acts as a peptidoglycan L,D transpeptidase [48]. The predicted α -monoglucosyldiacylglycerol synthase gene *mgs* is orthologous (73% amino acid identity) to *bgsB* in *E. faecalis*, which is required for the biosynthesis of membrane glycolipids [49]. The *clsA_1* gene is predicted to be responsible for the synthesis of cardiolipin (bisphosphatidylglycerol) and its inactivation may modulate the physical properties of the cytoplasmic membrane [50]. Finally, *lytA_2* is predicted to encode an autolysin, which may be involved in the turnover of peptidoglycan in the cell wall [51]. The transposon mutants in these genes were not further characterized in this study, but our findings suggest that non-essential pathways of cell wall or cytoplasmic membrane remodelling may confer subtle fitness defects to *E. faecium* when growing in a nutrient-poor environment, like serum.

Our RNA-seq-based transcriptional profiling of *E. faecium* E745 during mid-exponential growth in serum showed pervasive changes in gene expression compared to exponential growth in rich medium. The large number of differentially expressed genes may not all reflect the different growth conditions (serum and BHI) per se, but could also be influenced by the difference in growth rate during mid-exponential growth in serum and BHI (Additional file 2). The purine metabolism genes *purL*, *purH*, *purD*, which were found to be required for growth in serum in our Tn-seq experiments, were among those that were significantly upregulated during growth in serum compared to growth in rich medium. Notably, a single prophage was expressed at higher levels during growth in serum than in rich medium. The abundance of prophage elements in the genome of *E. faecium* has been noted before [4, 52]. Interestingly, in the related

bacterium *Enterococcus faecalis* prophages encode platelet-binding proteins [53] and may have a role in intestinal colonization [54]. The contribution of *E. faecium* prophages to traits that are important for colonization and infection may provide important insights into the success of *E. faecium* as a nosocomial pathogen.

Conclusions

Our data indicate that nucleotide biosynthesis and carbohydrate metabolism are critical metabolic pathways for the proliferation and survival of *E. faecium* in the bloodstream. The proteins encoded by the genes required for growth in human serum that were identified in this study, could serve as candidates for the development of novel anti-infectives for the treatment of bloodstream-infections by multi-drug resistant *E. faecium*.

Methods

Bacterial strains, plasmids, growth conditions, and oligonucleotides

The vancomycin-resistant *E. faecium* strain E745 was used throughout this study. This strain was isolated from a rectal swab of a hospitalized patient, during routine surveillance of a VRE outbreak in a Dutch hospital [27, 28]. Unless otherwise mentioned, *E. faecium* was grown in brain heart infusion broth (BHI; Oxoid) at 37 °C. The *E. coli* strains DH5 α (Invitrogen) was grown in Luria-Bertani (LB) medium. When necessary, antibiotics were used at the following concentrations: chloramphenicol 4 $\mu\text{g ml}^{-1}$ for *E. faecium* and 10 $\mu\text{g ml}^{-1}$ for *E. coli*, and gentamicin 300 $\mu\text{g ml}^{-1}$ for *E. faecium* and 25 $\mu\text{g ml}^{-1}$ for *E. coli*. All antibiotics were obtained from Sigma-Aldrich. Growth was determined by measuring the optical density at 660 nm (OD₆₆₀). The sequences of all oligonucleotides used in this study are listed in Additional file 10.

Genome sequencing, assembly and bioinformatic analysis

E. faecium E745 was sequenced using a combination of Illumina HiSeq 100 bp paired-end sequencing, long-read sequencing using the Pacific Biosciences RS II SMRT technology and the MinION system with R7 flowcell chemistry (Oxford Nanopore Technologies). Corrected PacBio reads were assembled using the Celera assembler (version 8.1) [55] and assembled contigs were then corrected by aligning Illumina reads using BWA (version 0.7.9a), with default parameters for index creation and the BWA-MEM algorithm with the *-M* option for the alignment [56]. This approach resulted in 15 contigs, including one contig covering the entire 2.77 Mbp chromosome. After discarding contigs with low-coverage, the remaining contigs constituted 5 circular plasmid sequences and 5 non-overlapping contigs. These 5 contigs were aligned against the NCBI Genbank database and all were found to be part of the *E. faecium* plasmid pMG1 [57]. Based on

this alignment the presumed order of contigs was determined and confirmed by gap-spanning PCRs and sequencing of the products. A single gap between two contigs, could not be closed by PCR. Thus, we assembled Illumina reads together with MinION 2D reads using the SPAdes assembler (version 3.0) [58], which produced a contig that closed the gap, resulting in a complete assembly of this plasmid. Sequence coverage of chromosomal and plasmid sequences was determined with SAMtools (version 0.1.18) using short read alignments to the assembly, which were generated using BWA (version 0.7.9a). SAMtools was also used to identify possible base-calling and assembly errors, by aligning short reads to assembled contigs. A base was corrected using the consensus of aligned reads [59]. The corrected sequences were annotated using Prokka (version 1.10) [60]. A maximum likelihood phylogenetic tree based on the core genome of *E. faecium* E745 and an additional 72 *E. faecium* strains representing the global diversity of the species [4], was generated using ParSNP [61] with settings *-c* (forcing inclusion of all genome sequences) and *-x* (enabling recombination detection and filtering). The resulting phylogenetic tree was visualized using MEGA 7.0.26 [62]. Antibiotic resistance genes in the assembled genome sequence of *E. faecium* E745 were identified using ResFinder [63]. The annotated genome of *E. faecium* E745 is available from NCBI Genbank database under accession numbers CP014529 – CP014535.

RNA-seq

Approximately 3×10^7 cfu of *E. faecium* E745 were inoculated into 14 ml of BHI broth and heat-inactivated serum, and grown at 37 °C until exponential phase. Cultures were centrifuged at room temperature (15 s; 21.380 g), and pellets were flash frozen in liquid N₂ prior to RNA extraction, which was performed as described previously [21]. The ScriptSeq Complete Kit (Bacteria) (Epicentre Biotechnologies, WI) was used for rRNA removal and strand-specific library construction. Briefly, rRNA was removed from 2.5 μg of total RNA. To generate strand specific RNA-seq data, approximately 100 ng of rRNA-depleted RNA was fragmented and reverse transcribed using random primers containing a 5' tagging sequence, followed by 3' end tagging with a terminal-tagging oligo to yield di-tagged, single-stranded cDNA. Following magnetic-bead based purification, the di-tagged cDNA was amplified by PCR (15 cycles) using ScriptSeq Index PCR Primers (Epicentre Biotechnologies, WI). Amplified RNA-seq libraries were purified using AMPure XP System (Beckman Coulter) and sequenced by a 100 bp paired end reads sequencing run using the Illumina HiSeq 2500 platform (University of Edinburgh, United Kingdom). Data analysis was performed using Rockhopper [64] using the default settings for strand specific analysis.

Validation of RNA-seq results by quantitative real-time RT-PCR (qRT-PCR).

Total RNA isolated as described previously was used to confirm the transcriptome analysis by qRT-PCR. cDNA was synthesized as described above and qRT-PCR on these cDNAs was performed using the Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, Breda, The Netherlands) and a StepOnePlus instrument (Life Technologies). The expression of *tufA* was used as a housekeeping control. Ct values were calculated using the StepOne analysis software v2.2. Transcript levels, relative to *tufA*, of the assayed genes were calculated using REST 2009 V2.0.13 (Qiagen, Venlo, the Netherlands). This experiment was performed with three biological replicates.

Generation of *mariner* transposon mutant library in *E. faecium*

To create a transposon mutant library in *E. faecium* E745 suitable for Tn-seq, the *mariner* transposon cassette (carrying a gentamicin resistance gene) in the transposon delivery plasmid pZXL5 [21] was adapted as follows. The transposon from pZXL5 was amplified by PCR using the set of primers: pZXL5_MmeI_SacII_Fw and pZXL5_MmeI_SacII_Rv. These primers introduced MmeI restriction sites in the inverted repeats on both sides of the transposon. The modified transposon delivery vector, termed pGPA1, was generated by the digestion of pZXL5 with SacII, followed by the insertion of the SacII-digested *mariner* transposon that contained MmeI restriction sites at its extreme ends. pGPA1 was electroporated into *E. faecium* E745 and the transposon mutant library was generated by selecting for gentamicin-resistant transposon mutants as described previously [21].

Tn-seq analysis of conditionally essential genes in *E. faecium* E745

The transposon mutant library created in E745 was prepared for Tn-seq analysis, similar to previously described procedures [65]. To identify genes that are essential for the viability of *E. faecium* in BHI, we used ten experimental replicates of the mutant library. Aliquots (20 μ l) of the transposon mutant library, containing approximately 10^7 cfu, were used to inoculate 20 ml BHI broth and grown overnight at 37 °C. Subsequently, 1 ml aliquots of the cultures were spun down (15 s, 21,380 g) and used for the extraction of genomic DNA (Wizard genomic DNA purification kit, Promega Benelux). 2 μ g of the extracted DNA was digested for 4 h at 37 °C using 10 U MmeI (New England Biolabs) and immediately dephosphorylated with 1 U of calf intestine alkaline phosphatase (Invitrogen) during

30 min at 50 °C. DNA was isolated using phenol-chloroform extraction and subsequently precipitated using ethanol. The DNA pellets were then dissolved in 20 μ l water. The samples were barcoded and prepared for Tn-seq sequencing as described previously [65]. The sequence reads from all ten experimental replicates were mapped to the genome, and the mapped read-counts were then tallied for the analysis of the essentiality of the genes in the *E. faecium* E745 genome (further described below).

To identify genes that are required for growth in human serum, 20 μ l aliquots of the frozen mutant library in E745 were inoculated in BHI broth and grown overnight as described above. Subsequently, bacterial cells were washed with physiological saline solution. Approximately 3×10^7 cfu were inoculated into 14 ml BHI broth, and approximately 3×10^6 cfu were inoculated into 14 ml human serum obtained from Sigma (Cat. No. H4522; Sterile filtered type-AB human serum) or heat-inactivated human serum (the same, after incubation for 30 min at 56 °C). The different inoculum-sized were used in order for a similar number of divisions to occur during the experiment. Cells were incubated at 37 °C for 24 h without shaking and then further processed for Tn-seq [65]. This experiment was performed in triplicate.

Tn-seq samples were sequenced (50 nt, single-end) on one lane of a Illumina Hiseq 2500 (Baseclear, Leiden, the Netherlands and Sequencing facility University Medical Center, Utrecht, The Netherlands), generating an average of 15 million high quality reads per sample.

Tn-seq data analysis

Raw Illumina sequence reads from Illumina sequencing were split, based on their barcode, using the Galaxy platform [66], and 16-nucleotide fragments of each read that corresponded to E745 sequences, were mapped to the E745 genome using Bowtie 2 [67]. The results of the alignment were sorted and counted by IGV [68] using a 25-nucleotide window size and then summed over the gene. Read mapping to the final 10% of a gene were discarded as these insertions may not inactivate gene function. Read counts per gene were then normalized to the total number of reads that mapped to the genome in each replicate, by calculating the normalized read-count RPKM (Reads Per Kilobase per Million input reads) via the following formula: $RPKM = (\text{number of reads mapped to a gene} \times 10^6) / (\text{total mapped input reads in the sample} \times \text{gene length in kbp})$. Statistical analysis of the RPKM-values between the experimental conditions was performed using Cyber-T [69]. Genes were determined to be significantly contributing to growth in human serum when the Benjamini-Hochberg corrected *P*-value was <0.05 and the difference in

abundance of the transposon mutant during growth in BHI and serum was >2 .

Isolation of mutants from the transposon mutant library pool

To recover a targeted transposon mutant from the complete mutant pool, a PCR-based screening strategy was developed (Additional data file 9). 40 μ l of the transposon mutant library was inoculated into 40 ml of BHI broth with gentamicin and grown overnight at 37 °C with shaking (200 rpm). The overnight culture, containing approximately 10^9 cfu/ml, was then diluted to approximately 20 cfu/ml in 500 ml of BHI with gentamicin and kept on ice. Subsequently, 200 μ l aliquots were transferred to wells of sterile 96 wells plates ($n = 12$, Corning Inc.). After overnight incubation at 37 °C without shaking, aliquots (15 μ l) of each one of the 96 wells, were further pooled into a single new 96 well plate, as described in Additional file 9.

PCRs were performed on the final plate in which the transposon mutants were pooled, to check for the presence of the Tn-mutants of interest, using the primer ftp_tn_both_ends_MmeI, which is complementary to the repeats flanking the transposon sequence, in combination with a gene-specific primer. When a PCR was found to be positive in one of the wells of this plate, the location of the Tn-mutant was tracked backwards to the wells containing approximately 4 independent transposon mutants, by performing PCRs mapping the presence of the transposon mutant in each step. Cells from the final positive well were plated onto BHI with gentamicin and colony PCR was performed to identify the desired transposon mutant.

Growth of *E. faecium* E745 and individual mutants in human serum

Wild-type E745 and the mutant strains were grown overnight at 37 °C in BHI broth. Subsequently, bacterial cells were washed with physiological saline and approximately 3×10^5 cfu were inoculated into 1.4 ml BHI broth or heat-inactivated serum. Cells were grown in 1.5 ml tubes (Eppendorf) in triplicate for each condition and incubated at 37 °C for 24 h without shaking. Bacterial growth was determined by assessing viable counts, for which the cultures were serially diluted using physiological saline solution and plated onto BHI agar followed by overnight incubation at 37 °C.

Intravenous infection of zebrafish embryos

London wild-type (LWT) inbred zebrafish embryos, provided by the aquarium staff of The Bateson Center (University of Sheffield), were used for infection experiments. The parental E745 strain and its *pyrK_2* and

manY_2 transposon mutants were grown in BHI broth until they reached an optical density at 600 nm of approximately 0.5 and were then harvested by centrifugation (5500 g, 10 min). Bacteria were microinjected into the circulation of dechorionated zebrafish embryos at 30 h post fertilization, as previously described [70]. Briefly, anesthetized embryos were embedded in 3% (w/v) methylcellulose and injected individually with approximately 1.2×10^4 cfu using microcapillary pipettes. For each strain, 29 to 32 infected embryos were observed for survival up to 90 h post infection (hpi). This experiment was performed in triplicate.

Additional files

Additional file 1: Genome sequence information for *E. faecium* E745. (XLSX 10 kb)

Additional file 2: Growth of *E. faecium* E745 in BHI and serum. (PDF 962 kb)

Additional file 3: Operons identified by RNA-seq in *E. faecium* E745. (XLSX 40 kb)

Additional file 4: *E. faecium* E745 genes that exhibited significant ($q < 0.001$ and fold-change > 2) differential expression in human serum, as determined by RNA-seq. (XLSX 70 kb)

Additional file 5: qRT-PCR validation of RNA-seq experiments. Correlation of RNA-seq and qRT-PCR expression ratios for the seven genes with various expression levels and genomic locations. The gene expression ratios obtained from both qRT-PCR and RNA-seq were normalized by a housekeeping control gene *Efm745_00056 (tufA)*. The experiment was performed with three biological replicates. (PDF 121 kb)

Additional file 6: Characterization of the *E. faecium* E745 transposon mutant library, showing the number of reads that were mapped to the *E. faecium* E745 chromosome and plasmids. The height of each peak represents the read abundance at a specific insertion site. On the y-axis, the number of mapped reads is shown on a log scale. (PDF 1427 kb)

Additional file 7: Tn-seq data: comparison of heat-inactivated and native serum (XLSX 139 kb)

Additional file 8: *E. faecium* E745 genes that significantly ($q < 0.05$ and fold-change < -2 or > 2) contribute to growth in human serum, as identified by Tn-seq. (XLSX 13 kb)

Additional file 9: Isolation of mutants from the transposon mutant library pool. (A) Schematic representation of the PCR reaction designed to find a particular Tn-mutant within the transposon mutant library. This PCR uses a combination of a gene-specific primer (blue arrow) and a transposon specific primer (yellow arrow). Positive PCR products, indicated by the green check marks, should occur when the transposon (depicted as a yellow triangle) is inserted in the gene of interest (depicted in blue). If the transposons inserted in adjacent genes or intergenic regions, no PCR product can be amplified (red crosses). (B) Schematic workflow to isolate Tn-mutants from the mutant library. The transposon mutant library is split into 12 plates (A1 - A12) of 96 wells, with each 200 μ l well containing an average of 4 mutants. Plates were incubated overnight (Step 2). Plate A1 was then pooled into the first column of a new 96 well plate, denominated plate B1 (Step 3) and the same was done for plates A2 to A12. Subsequently, plate B1 was pooled again into the first column of a third plate, denominated C1 (Step 4). PCR using the gene-specific primer and the transposon specific primer was performed on the 8 wells of plate C1 (Step 5). A positive PCR was suggestive of the presence of a particular transposon-mutant (depicted as a red dot). The presence of the transposon mutant was then confirmed by PCR in plate B1 (step 6) and the corresponding plate A (step 7). Once a transposon-mutant was located to a particular well in plate A, the well was plated on BHI plates containing gentamicin, and

the colonies were screened for the presence of the transposon mutant by PCR (step 8). (PDF 277 kb)

Additional file 10: Oligonucleotides used in this study. (XLSX 10 kb)

Abbreviations

BHI: Brain Heart Infusion broth; cDNA: complementary DNA; cfu: colony forming units; hpi: hours post-infection; kbp: kilo-base pair; LB: Luria-Bertani; LWT: London wild-type; NCBI: National Center for Biotechnology Information; nt: nucleotides; PTS: phosphotransferase system; qPCR: quantitative polymerase chain reaction; RNA-seq: RNA sequencing; RPKM: reads per kilobase per million input reads; rRNA: ribosomal RNA; Tn-seq: transposon sequencing; TraDIS: transposon directed insertion sequencing; U: unit(s)

Acknowledgements

Not applicable.

Funding

This work was supported by the European Union Seventh Framework Programme (FP7-HEALTH-2011-single-stage) "Evolution and Transfer of Antibiotic Resistance" (EvoTAR) under grant agreement number 282004 and by a grant from the Netherlands Organization for Scientific Research (VIDI: 917.13.357) to W.v.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Sequence reads generated in this study have been made available at the European Nucleotide Archive under accession number PRJEB19025. The core genome alignment and Newick-formatted tree file that were generated for Fig. 1, are available in the Figshare repository (<https://doi.org/10.6084/m9.figshare.5545327.v1>). Strains and vectors can be requested by contacting the corresponding author.

Authors' contributions

XZ, VdM, AMGP, and TKP performed experiments. JRB, MdB and MRCR contributed bioinformatic analyses. XZ, MJMB, SM, RW and WvS designed the study. XZ, AMGP, JRB and WvS drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Strain E745 was isolated as part of routine diagnostic procedures during a VRE outbreak. This aspect of the study did not require consent or ethical approval by an institutional review board. Zebrafish work was performed according to guidelines and legislation set out in United Kingdom law under the Animals (Scientific Procedures) Act 1986. Ethical approval was given by the University of Sheffield Local Ethical Review Panel. All zebrafish experiments in this study were performed on larvae before the free feeding stage (5.2 days post fertilization) and consequently did not fall under the animal experimentation law according to the Act.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou 310058, China. ²Department of Medical Microbiology, University Medical Center Utrecht, 3584CX Utrecht, the Netherlands. ³Krebs Institute, University of Sheffield, Sheffield S10 2TN, United Kingdom. ⁴Institute of Microbiology and Infection, College of Medical and Dental Sciences, The University of Birmingham, Birmingham B15 2TT, United Kingdom.

Received: 9 May 2017 Accepted: 13 November 2017

Published online: 21 November 2017

References

- Dupont H, Friggeri A, Touzeau J, Airapetian N, Tinturier F, Lobjoie E, et al. Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit. *J Antimicrob Chemother.* 2011;66:2379–85.
- Guzman Prieto AM, van Schaik W, Rogers MRC, Coque TM, Baquero F, Corander J, et al. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? *Front Microbiol.* 2016;7:788.
- Arias CA, Murray BE. The rise of the *Enterococcus*: beyond vancomycin resistance. *Nat Rev Microbiol.* 2012;10:266–78.
- Lebreton F, van Schaik W, Manson McGuire A, Godfrey P, Griggs A, Mazumdar V, et al. Emergence of epidemic multidrug-resistant *Enterococcus faecium* from animal and commensal strains. *MBio.* 2013;4:e00534–13.
- Zhang X, Top J, de Been M, Bierschen D, Rogers M, Leendertse M, et al. Identification of a genetic determinant in clinical *Enterococcus faecium* strains that contributes to intestinal colonization during antibiotic treatment. *J Infect Dis.* 2013;207:1780–6.
- Heikens E, Singh KV, Jacques-Palaz KD, Van Luit-Asbroek M, Oostdijk EAN, Bonten MJM, et al. Contribution of the enterococcal surface protein Esp to pathogenesis of *Enterococcus faecium* endocarditis. *Microbes Infect.* 2011;13:1185–90.
- Paganelli FL, Huebner J, Singh KV, Zhang X, van Schaik W, Wobser D, et al. Genome-wide screening identifies phosphotransferase system permease BepA to be involved in *Enterococcus faecium* endocarditis and biofilm formation. *J Infect Dis.* 2016;214:189–95.
- Sillanpää J, Prakash VP, Nallapareddy SR, Murray BE. Distribution of genes encoding MSCRAMMs and pili in clinical and natural populations of *Enterococcus faecium*. *J Clin Microbiol.* 2009;47:896–901.
- Montealegre MC, Singh KV, Somarajan SR, Yadav P, Chang C, Spencer R, et al. Role of the Emp pilus subunits of *Enterococcus faecium* in biofilm formation, adherence to host extracellular matrix components, and experimental infection. *Infect Immun.* 2016;84:1491–500.
- Kamboj M, Blair R, Bell N, Sun J, Eagan J, Sepkowitz K. What is the source of bloodstream infection due to vancomycin-resistant enterococci in persons with mucosal barrier injury? *Infect Control Hosp Epidemiol.* 2014;35:99–101.
- de Regt MJA, van Schaik W, van Luit-Asbroek M, Dekker HAT, van Duijkeren E, Koning CJM, et al. Hospital and community ampicillin-resistant *Enterococcus faecium* are evolutionarily closely linked but have diversified through niche adaptation. *PLoS One.* 2012;7:e30319.
- Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al. Vancomycin-resistant *Enterococcus* domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. *J Clin Invest.* 2010;120:4332–41.
- Bouza E, Kestler M, Beca T, Mariscal G, Rodríguez-Crèixems M, Bermejo J, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. *Clin Infect Dis.* 2015;60:528–35.
- Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. *Expert Rev Anti-Infect Ther.* 2008;6:637–55.
- Coombs GW, Pearson JC, Daly DA, Le TT, Robinson JO, Gottlieb T, et al. Australian Enterococcal sepsis outcome Programme annual report, 2013. *Commun Dis Intell Q Rep.* 2014;38:E320–6.
- de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European antimicrobial resistance surveillance system. *Clin Microbiol Infect.* 2013;19:860–8.
- Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. *Infect Control Hosp Epidemiol.* 2008;29:996–1011.
- Krebs HA. Chemical composition of blood plasma and serum. *Annu Rev Biochem.* 1950;19:409–30.
- van Opijnen T, Camilli A. Transposon insertion sequencing: a new tool for systems-level analysis of microorganisms. *Nat Rev Microbiol.* 2013;11:435–42.
- Barquist L, Boinett CJ, Cain AK. Approaches to querying bacterial genomes with transposon-insertion sequencing. *RNA Biol.* 2013;10:1161–9.

21. Zhang X, Paganelli FL, Bierschenk D, Kuipers A, Bonten MJM, Willems RJL, et al. Genome-wide identification of ampicillin resistance determinants in *Enterococcus faecium*. PLoS Genet. 2012;8:e1002804.
22. Zhang X, Bierschenk D, Top J, Anastasiou I, Bonten MJ, Willems RJ, et al. Functional genomic analysis of bile salt resistance in *Enterococcus faecium*. BMC Genomics. 2013;14:299.
23. Prieto AMG, Wijngaarden J, Braat JC, Rogers MRC, Majoor E, Brouwer EC, et al. The two component system ChtRS contributes to chlorhexidine tolerance in *Enterococcus faecium*. Antimicrob Agents Chemother. 2017;61:e02122–16.
24. van Opijnen T, Bodi KL, Camilli A. Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nat Methods. 2009;6:767–72.
25. Langridge GC, Phan M-D, Turner DJ, Perkins TT, Parts L, Haase J, et al. Simultaneous assay of every *Salmonella Typhi* gene using one million transposon mutants. Genome Res. 2009;19:2308–16.
26. van Opijnen T, Lazinski DW, Camilli A. Genome-wide fitness and genetic interactions determined by Tn-seq, a high-throughput massively parallel sequencing method for microorganisms. Curr Protoc Microbiol. 2015;36:1E.3.1–1E.3.24.
27. Leavis HL, Willems RJL, van Wamel WJB, Schuren FH, Caspers MPM, Bonten MJM. Insertion sequence-driven diversification creates a globally dispersed emerging multiresistant subspecies of *E faecium*. PLoS Pathog. 2007;3:e7.
28. Mascini EM, Troelstra A, Beitsma M, Blok HEM, Jalink KP, Hopmans TEM, et al. Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant *Enterococcus faecium*. Clin Infect Dis. 2006;42:739–46.
29. van Schaik W, Top J, Riley DR, Boekhorst J, Vrijenhoek JEP, Schapendonk CME, et al. Pyrosequencing-based comparative genome analysis of the nosocomial pathogen *Enterococcus faecium* and identification of a large transferable pathogenicity island. BMC Genomics. 2010;11:239.
30. Heikens E, Bonten MJ, Willems RJ. Enterococcal surface protein Esp is important for biofilm formation of enterococcus faecium E1162. J Bacteriol. 2007;189:8233–40.
31. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis. 2006;42:S25–34.
32. Sekiguchi J, Tharavichitkul P, Miyoshi-Akiyama T, Chupia V, Fujino T, Araake M, et al. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of *Staphylococcus aureus* CMS2 (IMCJ1454). Antimicrob Agents Chemother. 2005;49:3948–51.
33. Singh KV, Malathum K, Murray BE. Disruption of an *Enterococcus faecium* species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. Antimicrob Agents Chemother. 2001;45:263–6.
34. Joisel F, Leroux-Nicollet I, Lebreton JP, Fontaine MA. Hemolytic assay for clinical investigation of human C2. J Immunol Methods. 1983;59:229–35.
35. Berends ETM, Dekkers JF, Nijland R, Kuipers A, Soppe JA, van Strijp JAG, et al. Distinct localization of the complement C5b-9 complex on gram-positive bacteria. Cell Microbiol. 2013;15:1955–68.
36. Pence MA, Rooijakkers SHM, Cogen AL, Cole JN, Hollands A, Gallo RL, et al. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive MIT1 group A *Streptococcus*. J Innate Immun. 2010;2:587–95.
37. Prajsnar TK, Renshaw SA, Ogrzyko NV, Foster SJ, Serror P, Mesnage S. Zebrafish as a novel vertebrate model to dissect enterococcal pathogenesis. Infect Immun. 2013;81:4271–9.
38. Samant S, Lee H, Ghassemi M, Chen J, Cook JL, Mankin AS, et al. Nucleotide biosynthesis is critical for growth of bacteria in human blood. PLoS Pathog. 2008;4:e37.
39. Le Breton Y, Mistry P, Valdes KM, Quigley J, Kumar N, Tettelin H, et al. Genome-wide identification of genes required for fitness of group A *Streptococcus* in human blood. Infect Immun. 2013;81:862–75.
40. Jenkins A, Cote C, Twenhafel N, Merkel T, Bozue J, Welkos S. Role of purine biosynthesis in *Bacillus anthracis* pathogenesis and virulence. Infect Immun. 2011;79:153–66.
41. Polissi A, Pontiggia A, Feger G, Altieri M, Mottl H, Ferrari L, et al. Large-scale identification of virulence genes from *Streptococcus pneumoniae*. Infect Immun. 1998;66:5620–9.
42. Wang N, Ozer EA, Mandel MJ, Hauser AR. Genome-wide identification of *Acinetobacter baumannii* genes necessary for persistence in the lung. MBio. 2014;5:e01163–14.
43. Fuller TE, Kennedy MJ, Lowery DE. Identification of *Pasteurella multocida* virulence genes in a septicemic mouse model using signature-tagged mutagenesis. Microb Pathog. 2000;29:25–38.
44. Schwager S, Agnoli K, Kothé M, Feldmann F, Givskov M, Carlier A, et al. Identification of *Burkholderia cenocepacia* strain H111 virulence factors using nonmammalian infection hosts. Infect Immun. 2013;81:143–53.
45. Chaudhuri RR, Peters SE, Pleasance SJ, Northen H, Willers C, Paterson GK, et al. Comprehensive identification of *Salmonella enterica* serovar Typhimurium genes required for infection of BALB/c mice. PLoS Pathog. 2009;5:e1000529.
46. Mulhbachter J, Brouillette E, Allard M, Fortier L-C, Malouin F, Lafontaine DA. Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS Pathog. 2010;6:e1000865.
47. Castro R, Neves AR, Fonseca LL, Pool WA, Kok J, Kuipers OP, et al. Characterization of the individual glucose uptake systems of *Lactococcus lactis*: mannose-PTS, cellobiose-PTS and the novel GlcU permease. Mol Microbiol. 2009;71:795–806.
48. Mainardi J-L, Fourgeaud M, Hugonnet J-E, Dubost L, Brouard J-P, Ouazzani J, et al. A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway. J Biol Chem. 2005;280:38146–52.
49. Theilacker C, Sava I, Sanchez-Carballo P, Bao Y, Kropec A, Grohmann E, et al. Deletion of the glycosyltransferase *bgsB* of *Enterococcus faecalis* leads to a complete loss of glycolipids from the cell membrane and to impaired biofilm formation. BMC Microbiol. 2011;11:167.
50. Davlieva M, Zhang W, Arias CA, Shamoo Y. Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother. 2013;57:289–96.
51. Vollmer W, Joris B, Charlier P, Foster S. Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol Rev. 2008;32:259–86.
52. Mikalsen T, Pedersen T, Willems R, Coque TM, Werner G, Sadowy E, et al. Investigating the mobilome in clinically important lineages of *Enterococcus faecium* and *Enterococcus faecalis*. BMC Genomics. 2015;16:282.
53. Matos RC, Lapaque N, Rigottier-Gois L, Debarbieux L, Meylheuc T, Gonzalez-Zorn B, et al. *Enterococcus faecalis* prophage dynamics and contributions to pathogenic traits. Hughes D. PLoS Genet. 2013;9:e1003539.
54. Duerkop BA, Clements CV, Rollins D, Rodrigues JLM, Hooper LVA. Composite bacteriophage alters colonization by an intestinal commensal bacterium. Proc Natl Acad Sci. 2012;109:17621–6.
55. Goldberg SMD, Johnson J, Busam D, Feldblyum T, Ferreira S, Friedman R, et al. A Sanger/pyrosequencing hybrid approach for the generation of high-quality draft assemblies of marine microbial genomes. Proc Natl Acad Sci U S A. 2006;103:11240–5.
56. Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 2009;25:1754–60.
57. Tanimoto K, Ike Y. Complete nucleotide sequencing and analysis of the 65-kb highly conjugative *Enterococcus faecium* plasmid pMG1: identification of the transfer-related region and the minimum region required for replication. FEMS Microbiol Lett. 2008;288:186–95.
58. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77.
59. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.
60. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–9.
61. Treangen TJ, Ondov BD, Koren S, Phillippy AM. The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. Genome Biol. 2014;15:524.
62. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:1870–4.
63. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–4.
64. McClure R, Balasubramanian D, Sun Y, Bobrovskyy M, Sumbly P, Genco CA, et al. Computational analysis of bacterial RNA-Seq data. Nucleic Acids Res. 2013;41:e140.
65. Burghout P, Zomer A, van der Gaast-de Jongh CE, Janssen-Megens EM, François K-J, Stunnenberg HG, et al. *Streptococcus pneumoniae* folate biosynthesis responds to environmental CO₂ levels. J Bacteriol. 2013;195:1573–82.

66. Goecks J, Nekrutenko A, Taylor J. Galaxy team. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. *Genome Biol.* 2010;11:R86.
67. Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. *Nat Methods.* 2012;9:357–9.
68. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. *Nat Biotechnol.* 2011;29:24–6.
69. Baldi P, Long ADA. Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. *Bioinformatics.* 2001;17:509–19.
70. Prajsnar TK, Cunliffe VT, Foster SJ, Renshaw SAA. Novel vertebrate model of *Staphylococcus aureus* infection reveals phagocyte-dependent resistance of zebrafish to non-host specialized pathogens. *Cell Microbiol.* 2008;10:2312–25.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

